Choose the brand aligned with your industry so we can best serve your needs.
For researchers, scientists, and technical professionals: Your one-stop shop for the complete range of laboratory, production, and safety products and services.
The BD Veritor™ Plus System enhances point-of-care testing for SARS-CoV-2,Flu A+B, RSV and Group A Strep assays, providing rapid diagnostic testing in a convenient, portable instrument.
GSA/VA Contract Available on GSA/VA contract for Federal Government customers. Learn More
Intended for the rapid, qualitative detection of respiratory syncytial virus (RSV) directly from nasopharyngeal swab and nasal aspirate specimens in those under the age of 6 or over the age of 60. Intended for use as an aid in the diagnosis of patients with symptoms consistent with RSV infection.
The Fisher Healthcare™ Sure-Vue™ Signature Rubella Test is a rapid latex particle agglutination test for the qualitative and semiquantitative determination of rubella virus antibodies in serum.
The Sure-Vue Color Mono II Test is a simple color-enhanced agglutination test for the qualitative and semiquantitative detection of heterophil antibodies in human serum or EDTA plasma associated with infectious mononucleosis (IM).
Rapid latex agglutination test used for detection of heterophile (Paul-Bunnell) antibodies associated with infectious mononucleosis in human serum or plasma.
VITROS™ Anti-SARS-CoV-2 IgG test is used for the qualitative detection of IgG antibodies to SARS-CoV-2 in human serum. Intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.
VITROS™ Anti-SARS-CoV-2 IgG test is used for the qualitative detection of IgG antibodies to SARS-CoV-2 in human serum. Intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.
Used for the qualitative measurement of total antibody (including IgG and IgM) to SARS-CoV-2 in human serum and plasma (K2 EDTA) samples from patients suspected of COVID-19 by a healthcare provider, using VITROS™ ECi/ECiQ/3600 Immunodiagnostic Systems and the VITROS™ 5600/XT 7600 Integrated Systems.